At present, the main treatment of tongue carcinoma is surgery, and chemoradiation is also important in advanced stage patients[26]. However, these treatments damage patients’ appearance, cause psychosocial problems, and lead to functional defect, particularly dysphagia[27, 28]. Some other severe complications are found in these therapies, which seriously influence the quality of life. Therefore, exploring ways at a molecular level is of great importance to improve patient prognosis.
As a post-translational modification of proteins, ubiquitination plays an important role in many biological functions, such as proliferation, apoptosis and differentiation[29, 30]. TRAIP is an E3 ubiquitin ligase, which has a RING finger motif and an extended coiled-coil domain[31]. Bioinformatics and previous studies have pointed that TRAIP is involved in cell progression. In addition, TRAIP plays an important role in regulating replisome stability and DNA interstrand cross-links repair pathway option[32]. Considering the mammalian replicative stress response and as a factor interacting with the proliferation cell nuclear antigen, TRAIP contributes to the recovery of impaired DNA replication forks[33]. TRAIP regulates mitotic process by regulating the spindle assembly checkpoint and it’s crucial to early mitotic process and arrangement of metaphase chromosomes[34]. Our research suggested that TRAIP is highly expressed in TSCC and closely related to the prognosis of patients. Therefore, TRAIP might promote the malignant behavior of TSCC. Our in vivo and in vitro experimental results also showed that TRAIP may stimulate the proliferation, migration and invasion of TSCC cells. Reports had suggested that TRAIP overexpression can increase the cell proliferation and metastatic ability in liver cancer, lung cancer, osteosarcoma and triple-negative breast cancer[10–12], these findings were consistent with our experimental results. However, TRAIP plays the opposite role in some tumors[35, 36]. In choroidal melanoma, TRAIP overexpression weakens the ability of choroidal melanoma cells to proliferate, migrate and invade and inhibits EMT progression because of its ability to ubiquitinate Twist1, thereby mediating its proteasomal degradation[35]. Kong LR et al. showed that TRAIP dephosphorylates IĸB and impedes the nuclear translocation of RelA (p65), thereby repressing oncogenic nuclear factor kappa-B (NF-ĸB) signaling and inducing apoptosis[36]. This condition can often be explained by the fact that the same gene may play different roles in different types of tumors, such as DNA-binding protein inhibitor 4 (ID4). In prostate cancer, ID4 is epigenetically silenced and acts as a tumor suppressor[37]. However, ID4 is a potential oncogene in bladder cancer and colorectal cancer[38]. In addition, studies have shown that in some cases, the high expression of the tumor suppressor PTEN may lead to the proliferation and invasion of pre-B acute lymphoblastic leukemia cells, resulting in a poor prognosis[39]. These studies suggest that the role and impact of a gene may vary depending on factors such as cell type, tumor type and genetic environment.
Our research also showed that silencing TRAIP induces G1 cell cycle arrest in TSCC cells, which consists with the role of TRAIP in foreskin keratinocyte[38]. After silencing TRAIP or DDX39A, the expression of cyclinD1 was decreased. The main function of cyclinD1 is to promote cell proliferation[40]. CyclinD1 binds to and activates the G1-phase unique cyclin-dependent kinase CDK4, which is phosphorylated by the G1 phase cycle inhibitor protein (Rb). Moreover, the phosphorylated Rb protein is dissociated from the E2F transcription factor to which it binds, and the E2F transcription factor initiates the transcription of genes in the living cell cycle, thereby promoting the cell cycle from the G1 phase to the S phase[41, 42]. We hypothesized that TRAIP and DDX39A cause cell cycle arrest by inhibiting cyclinD1 expression.
In this study, mass spectrometry, bioinformatics and Co-IP were used to identify the factor that plays a role with TRAIP in the progression of TSCC and DDX39A was selected. DDX39A belongs to the DEAD RNA helicase family, which is related to several cell processes, such as cells growth, migration, apoptosis, cytoskeletal rearrangement and RNA translocation[43]. Reports have suggested that DDX39A promotes cell growth and metastasis in hepatocellular carcinoma, melanoma and lung squamous cell carcinoma[44]. However, DDX39A inhibits the invasion ability of bladder cancer cells[45]. These studies suggest that DDX39A may play completely opposite roles in different tumors. By performing bioinformatics analysis, we found that DDX39A was highly expressed in TSCC tissue compared with normal tissue. We prove that DDX39A is the interacting protein of TRAIP, and HELICc domain of DDX39A is the key to interact with TRAIP.The interaction of TRAIP and DDX39A can regulate the proliferation, migration, invasion abilities and cell cycle progression in TSCC. Furthermore, our results showed that DDX39A and TRAIP enhanced TSCC migration and invasion via EMT pathway and Wnt/β-catenin signaling. Reports have indicated that DDX39A was highly expressed in several carcinomas, which can promote tumors progression, for instance, renal clear cell carcinoma, melanoma, hepatocellular carcinoma and breast cancer[46, 47]. These studies were in accordance with our findings. DDX39A was also related to chemoresistance in ER positive breast cancer and human pancreatic cancer[47, 48]. This protein may be an important immune checkpoint for it can cause tumor immune escape in renal clear cell carcinoma[46]. Therefore, the interaction of TRAIP and DDX39A is of great importance in TSCC progression.
The Wnt/β-catenin pathway is crucial to cell proliferation and metastasis, and during the activation of Wnt/β-catenin pathway, β-catenin accumulates in the cytoplasm, then enters the nucleus and interacts with T-cell factor/lymphoid enhancer factor (TCF/LEF), activating Wnt target genes, leading to tumorigenesis and metastasis[49]. EMT is a key process of cancer cell metastasis, during which epithelial cells acquired the characteristics of mesenchymal cells, enhanced cell motility and increased migration ability[50]. Research showed that DDX39A promotes hepatocellular carcinoma growth and metastasis by activating Wnt/β-catenin pathway[44]. However, studies related to DDX39A and EMT have not been reported. Our research indicated that TRAIP and DDX39A could regulate cell progression through EMT and Wnt/β-catenin pathway.
Up to now, this study is the first to investigate (1) TRAIP expression in TSCC and its relationship with clinicopathological characteristics of TSCC patients, (2) the effect of TRAIP and DDX39A on progression of TSCC cells, (3) the interaction of TRAIP and DDX39A in TSCC progression, (4) the mechanism by which the two factors regulate tumor malignant behaviors. Our research indicates that TRAIP and DDX39A may be potential treatment targets in TSCC.